Employees Provident Fund Board’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $210M | Buy |
3,640,333
+1,131,333
| +45% | +$65M | 1.2% | 28 |
|
|
2026
Q1 | $152M | Buy |
2,509,000
+450,000
| +22% | +$26.2M | 1.15% | 31 |
|
|
2025
Q4 | $111M | Buy |
2,059,000
+81,000
| +4% | +$3.9M | 0.82% | 38 |
|
|
2025
Q3 | $89.2M | Hold |
1,978,000
| – | – | 0.72% | 39 |
|
|
2025
Q2 | $91.6M | Buy |
1,978,000
+152,140
| +8% | +$7.47M | 0.79% | 38 |
|
|
2025
Q1 | $111M | Sell |
1,825,860
-1,040,726
| -36% | -$60.7M | 1.26% | 32 |
|
|
2024
Q4 | $162M | Sell |
2,866,586
-6,600
| -0.2% | -$369K | 2.01% | 12 |
|
|
2024
Q3 | $149M | Buy |
2,873,186
+402,799
| +16% | +$18.9M | 2.03% | 12 |
|
|
2024
Q2 | $103M | Buy |
2,470,387
+89,923
| +4% | +$4.02M | 1.64% | 21 |
|
|
2024
Q1 | $129M | Buy |
2,380,464
+632,530
| +36% | +$32.2M | 2.26% | 11 |
|
|
2023
Q4 | $89.7M | Buy |
1,747,934
+40,416
| +2% | +$2.12M | 1.75% | 23 |
|
|
2023
Q3 | $99.1M | Buy |
1,707,518
+1,176,222
| +221% | +$72.1M | 2.24% | 13 |
|
|
2023
Q2 | $34M | Buy |
531,296
+415,887
| +360% | +$27.9M | 0.8% | 40 |
|
|
2023
Q1 | $8M | Buy |
+115,409
| New | +$8.14M | 0.21% | 59 |
|
|
2022
Q3 | – | Sell |
-724,371
| Closed | -$55.8M | – | 82 |
|
|
2022
Q2 | $55.8M | Sell |
724,371
-111,808
| -13% | -$8.52M | 1.26% | 32 |
|
|
2022
Q1 | $61.1M | Sell |
836,179
-117,687
| -12% | -$7.9M | 1.05% | 34 |
|
|
2021
Q4 | $59.5M | Buy |
953,866
+68,675
| +8% | +$4.03M | 0.98% | 36 |
|
|
2021
Q3 | $52.4M | Hold |
885,191
| – | – | 0.86% | 44 |
|
|
2021
Q2 | $59.1M | Hold |
885,191
| – | – | 0.98% | 40 |
|
|
2021
Q1 | $55.9M | Hold |
885,191
| – | – | 0.96% | 39 |
|
|
2020
Q4 | $54.9M | Buy |
885,191
+210,749
| +31% | +$13M | 0.93% | 39 |
|
|
2020
Q3 | $40.7M | Buy |
674,442
+210,110
| +45% | +$12.6M | 0.85% | 38 |
|
|
2020
Q2 | $27.3M | Buy |
464,332
+92,933
| +25% | +$5.56M | 0.62% | 46 |
|
|
2020
Q1 | $20.7M | Sell |
371,399
-77,651
| -17% | -$4.75M | 0.56% | 44 |
|
|
2019
Q4 | $28.8M | Buy |
449,050
+418,158
| +1,354% | +$23.9M | 0.61% | 45 |
|
|
2019
Q3 | $1.57M | Buy |
+30,892
| New | +$1.45M | 0.04% | 52 |
|
|
2017
Q2 | – | Sell |
-678,000
| Closed | -$36.9M | – | 53 |
|
|
2017
Q1 | $36.9M | Buy |
678,000
+279,950
| +70% | +$15.4M | 1.08% | 36 |
|
|
2016
Q4 | $23.3M | Buy |
398,050
+74,386
| +23% | +$4.07M | 0.8% | 34 |
|
|
2016
Q3 | $17.5M | Buy |
+323,664
| New | +$20.8M | 0.62% | 35 |
|
|
2015
Q4 | – | Sell |
-43,650
| Closed | -$2.58M | – | 45 |
|
|
2015
Q3 | $2.58M | Buy |
+43,650
| New | +$2.77M | 0.1% | 45 |
|
Other funds holding BMY
Employees Provident Fund Board's BMY Position: Q2 2026 in Review
Employees Provident Fund Board increased its Bristol-Myers Squibb (BMY) stake by 45% in Q2 2026, buying an estimated $65M and bringing the position to 3,640,333 shares worth $210M. The position accounts for 1.2% of the portfolio, ranked #28.
Employees Provident Fund Board first reported a position in BMY in Q3 2015 and has held it in 30 quarters since. 2,506 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Employees Provident Fund Board held 3,640,333 shares of Bristol-Myers Squibb worth $210M as of Q2 2026.
- Employees Provident Fund Board bought 1,131,333 Bristol-Myers Squibb shares in Q2 2026, an estimated $65M.
- Bristol-Myers Squibb made up 1.2% of Employees Provident Fund Board's portfolio in Q2 2026, its #28 holding.
- Employees Provident Fund Board first reported a position in Bristol-Myers Squibb in Q3 2015 and has held it in 30 quarters since.
- 2,506 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Employees Provident Fund Board's 13F filing for Q2 2026, filed 12 Aug 2026.